Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review
- 338 Downloads
Clinical pharmacology (CP) is a multidisciplinary scientific field involving all aspects of the relationship between drugs and humans, encompassing professionals with a wide variety of skills including medicine, pharmacology, pharmacy, and biomedical science. The term “clinical pharmacologist” is commonly used in the professional sense to refer to medical doctors or PhD-level natural scientists/pharmacists with proven experience in improving patient care by developing new medicines and promoting the safer and more effective use of drugs. Clinical pharmacologists today should have experience even in various phases of drug development in basic and clinical research, regulatory agencies, and/or the pharmaceutical industry.
There was an important debate in 2006 that tried to define the main mission of CP [1, 2], identifying at least three priorities: First, CP is a laboratory discipline dealing with biomarkers, pharmacokinetics (PK), drug metabolism, and genetics. Second, CP is...
The authors would like to acknowledge Professor David Webb and Doctor Lee Page of British Pharmacological Society, Professor Alexander Jetter of Klinik für Klinische Pharmakologie und Toxikologie, Zurich. The authors would also like to acknoweledge Omar Alexander for his contributions in the linguistic revising.
DG and VAC were responsible for the study concept and design under the supervision of FS. The literature search, abstract screening, and data extraction were undertaken by DG with further confirmation by AC, GS and VAC. DG wrote the manuscript that was reviewed by AC. All the authors have read and approved the final manuscript submitted.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 13.Thomson S, Figueras J, Evetovits T et al (2014) Economic crisis, health systems and health in Europe: impact and implications for policy. WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies. http://www.euro.who.int/en/about-us/partners/observatory/publications/studies/economic-crisis,-health-systems-and-health-in-europe.-impact-and-implications-for-policy-2015. Accessed 15 april 2017
- 21.Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance. Available at: https://publications.europa.eu/en/publication-detail/-/publication/c1ad51e2-2e32-11e2-ad46-01aa75ed71a1. Accessed 20 April 2017
- 22.Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 ("Clinical Trials Directive"). Available at: https://ec.europa.eu/health/human-use/clinical-trials/directive_en. Accessed 20 April 2017
- 23.Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Available at: http://eur-lex.europa.eu Accessed 20 April 2017
- 24.Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at: http://eur-lex.europa.eu. Accessed 20 April 2017
- 25.Clinical Pharmacology in Health Care, Teaching and Research. Geneva: Council for the International Organizations of Medical Sciences; (2012). Available at: http://apps.who.int/medicinedocs/documents/s19916en/s19916en.pdf. Accessed 12 April 2017